InvestorsHub Logo
Followers 21
Posts 1791
Boards Moderated 0
Alias Born 03/07/2014

Re: None

Thursday, 12/14/2023 11:50:37 AM

Thursday, December 14, 2023 11:50:37 AM

Post# of 384
8k out
"Following the FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive
events, bluebird bio, Inc. (the “Company”) has signed an outcomes-based agreement with an organization representing approximately 100 million covered
lives in the U.S. Additionally, the Company is in advanced discussions with a number of the nation’s other large commercial payers and more than 15
Medicaid agencies collectively representing 80% of individuals with sickle cell disease in the U.S. The Company anticipates 85 to 105 patient starts (cell
collections) combined across all three of its commercial products (LYFGENIA, ZYNTEGLO, SKYSONA) in 2024."

https://investor.bluebirdbio.com/static-files/a9da7005-b393-4e1b-bf28-71850b6a47a8
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News